Suessmuth Yvonne, Mukherjee Rithun, Watkins Benjamin, Koura Divya T, Finstermeier Knut, Desmarais Cindy, Stempora Linda, Horan John T, Langston Amelia, Qayed Muna, Khoury Hanna J, Grizzle Audrey, Cheeseman Jennifer A, Conger Jason A, Robertson Jennifer, Garrett Aneesah, Kirk Allan D, Waller Edmund K, Blazar Bruce R, Mehta Aneesh K, Robins Harlan S, Kean Leslie S
The Emory Transplant Center, Emory University School of Medicine, Atlanta, GA;
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle WA;
Blood. 2015 Jun 18;125(25):3835-50. doi: 10.1182/blood-2015-03-631853. Epub 2015 Apr 7.
Although cytomegalovirus (CMV) reactivation has long been implicated in posttransplant immune dysfunction, the molecular mechanisms that drive this phenomenon remain undetermined. To address this, we combined multiparameter flow cytometric analysis and T-cell subpopulation sorting with high-throughput sequencing of the T-cell repertoire, to produce a thorough evaluation of the impact of CMV reactivation on T-cell reconstitution after unrelated-donor hematopoietic stem cell transplant. We observed that CMV reactivation drove a >50-fold specific expansion of Granzyme B(high)/CD28(low)/CD57(high)/CD8(+) effector memory T cells (Tem) and resulted in a linked contraction of all naive T cells, including CD31(+)/CD4(+) putative thymic emigrants. T-cell receptor β (TCRβ) deep sequencing revealed a striking contraction of CD8(+) Tem diversity due to CMV-specific clonal expansions in reactivating patients. In addition to querying the topography of the expanding CMV-specific T-cell clones, deep sequencing allowed us, for the first time, to exhaustively evaluate the underlying TCR repertoire. Our results reveal new evidence for significant defects in the underlying CD8 Tem TCR repertoire in patients who reactivate CMV, providing the first molecular evidence that, in addition to driving expansion of virus-specific cells, CMV reactivation has a detrimental impact on the integrity and heterogeneity of the rest of the T-cell repertoire. This trial was registered at www.clinicaltrials.gov as #NCT01012492.
尽管长期以来巨细胞病毒(CMV)再激活一直被认为与移植后免疫功能障碍有关,但驱动这一现象的分子机制仍未明确。为解决这一问题,我们将多参数流式细胞术分析和T细胞亚群分选与T细胞受体库的高通量测序相结合,以全面评估CMV再激活对无关供体造血干细胞移植后T细胞重建的影响。我们观察到,CMV再激活促使颗粒酶B(高表达)/CD28(低表达)/CD57(高表达)/CD8(+)效应记忆T细胞(Tem)特异性扩增超过50倍,并导致所有幼稚T细胞(包括CD31(+)/CD4(+)假定胸腺迁出细胞)相应收缩。T细胞受体β(TCRβ)深度测序显示,由于再激活患者中CMV特异性克隆扩增,CD8(+)Tem多样性显著收缩。除了探究扩增的CMV特异性T细胞克隆的特征外,深度测序还使我们首次能够详尽评估潜在TCR受体库。我们的结果揭示了CMV再激活患者潜在CD8 Tem TCR受体库存在重大缺陷的新证据,首次提供了分子证据表明,除了驱动病毒特异性细胞扩增外,CMV再激活还对其余T细胞受体库的完整性和异质性产生有害影响。该试验已在www.clinicaltrials.gov上注册,注册号为#NCT01012492。